Zolbetuximab治疗胃癌的研究进展

Research Progress of Zolbetuximab in the Treatment of Gastric Cancer

胃癌是消化系统常见恶性肿瘤之一,对于微卫星不稳定/错配修复缺陷、人表皮生长因子受体2和PD-L1阳性胃癌患者,虽然免疫治疗及靶向治疗取得了一定进展,但生存率仍较低。紧密连接蛋白(Claudin proteins,Claudins)家族的CLDN18.2存在于多种肿瘤组织,与肿瘤的发生及进展密切相关,其在胃癌及其转移瘤中表达具有特异性。全文重点介绍CLDN18.2单抗Zolbetuximab治疗胃癌的研究进展。

Gastric cancer is one of the common malignant tumors in the digestive system.For patients with microsatellite instability/mismatch repair defects,human epidermal growth factor receptor 2 and PD-L1 positive gastric cancer,although immunotherapy and targeted therapy have made some progress,the survival rate is still low.The CLDN18.2 of the Claudin proteins(Claudins) family is present in various tumor tissues and is closely related to the occurrence and progression of tumors.Its expression is specific in gastric cancer and its metastases.This paper focuses on the research progress of CLDN18.2 monoclonal antibody Zolbetuximab in the treatment of gastric cancer.